Laverock Therapeutics Secures Over £20M in Seed Financing
Deal News | Jun 30, 2025 | EOS Investment Management Limited (Eos Advisory)
Laverock Therapeutics, a gene control company based in London, has announced a significant expansion of its seed funding round, bringing its total raised to over £20 million. This funding was led by Calculus Capital, with contributions from major investors such as Eli Lilly, Mercia Ventures, and Eos Advisory, among others. A notable new participant is Norcliffe Capital. The funds are aimed at advancing Laverock's platform technologies, which have demonstrated enhanced tumor control in both primary T-cell and Macrophage programs, highlighting the company's potential in developing precision advanced therapies. CEO David Venables emphasized the role of this investment in supporting technology validation and forming strategic collaborations. The company is also enhancing its corporate identity to better showcase its progress and partnership opportunities.
Sectors
- Biotechnology
- Healthcare
- Private Equity and Venture Capital
Geography
- United Kingdom – Laverock Therapeutics is based in London, thereby situating the company and its funding activities primarily within the UK.
- Global – The involvement of international investors like Eli Lilly suggests a global interest and impact in Laverock's technological advancements.
Industry
- Biotechnology – The article revolves around Laverock Therapeutics, which is involved in developing advanced gene control therapies, a key innovation within the biotechnology sector.
- Healthcare – Laverock's focus on therapeutic programs targeting cancer positions it within the healthcare industry, emphasizing advancements in medical treatments.
- Private Equity and Venture Capital – The funding round involves multiple venture capital and private equity firms, crucial players in the investment ecosystem for emerging biotech companies.
Financials
- £20M+ – Total amount raised by Laverock Therapeutics in the expanded seed funding round.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Laverock Therapeutics | Target Company | Company | A gene control company focused on developing disease-responsive therapies using programmable and tunable gene control technologies. |
| Calculus Capital | Leading Investor | Company | A venture capital firm leading the current seed funding round for Laverock Therapeutics. |
| EOS Advisory | Investor | Company | A venture capital firm that has participated in the seed funding round for Laverock Therapeutics. |
| Eli Lilly and Company | Investor | Company | An existing investor in Laverock Therapeutics, participating in the seed funding round. |
| Mercia Ventures | Investor | Company | An existing investor contributing to Laverock's seed funding round. |
| Maven Capital Partners | Investor | Company | An investor involved in the seed funding round for Laverock. |
| Norcliffe Capital | New Investor | Company | A new investor in Laverock Therapeutics participating in the seed funding round. |
| David Venables | CEO of Laverock Therapeutics | Person | Chief Executive Officer of Laverock Therapeutics, overseeing the strategic direction and development of the company. |
| Elizabeth Klein | Investment Director at Calculus | Person | Investment Director at Calculus Capital, commenting on the investment in Laverock. |